BI Asset Management Fondsmaeglerselskab A S Has $4.07 Million Position in Edwards Lifesciences Corporation $EW

Key Points

• BI Asset Management Fondsmaeglerselskab A S has reduced its holdings in Edwards Lifesciences Corporation by 22.6%, selling 16,432 shares to hold a total of 56,187 shares valued at approximately $4,072,000.
• Wall Street analysts have increased price targets for Edwards Lifesciences, with several firms giving it "buy" ratings and a consensus price target of $85.90.
• Insider transactions have occurred, including significant sales by executives, with insiders selling a total of $1,897,762 in shares over the last ninety days.

BI Asset Management Fondsmaeglerselskab A S trimmed its position in shares of Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 22.6% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,187 shares of the medical research company's stock after selling 16,432 shares during the quarter. BI Asset Management Fondsmaeglerselskab A S's holdings in Edwards Lifesciences were worth $4,072,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in EW. Nuveen LLC bought a new position in shares of Edwards Lifesciences during the first quarter worth $330,881,000. Jennison Associates LLC raised its holdings in shares of Edwards Lifesciences by 34.3% during the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock worth $731,036,000 after acquiring an additional 2,576,383 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $92,631,000. Northern Trust Corp raised its holdings in shares of Edwards Lifesciences by 21.8% during the fourth quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company's stock worth $481,582,000 after acquiring an additional 1,165,845 shares during the period. Finally, Orbimed Advisors LLC acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $84,787,000. 79.46% of the stock is owned by institutional investors.

Analysts Set New Price Targets

EW has been the topic of a number of research analyst reports. Robert W. Baird raised their price objective on shares of Edwards Lifesciences from $78.00 to $79.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. William Blair upgraded shares of Edwards Lifesciences to a "strong-buy" rating in a research note on Friday, July 25th. Wall Street Zen upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Barclays lifted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company an "overweight" rating in a research note on Friday, July 25th. Finally, Morgan Stanley lifted their price objective on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company an "equal weight" rating in a research report on Tuesday, July 15th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $85.90.

Edwards Lifesciences Stock Performance

Shares of EW stock traded up $0.31 during midday trading on Tuesday, hitting $81.17. 570,875 shares of the company were exchanged, compared to its average volume of 4,493,693. The firm has a market capitalization of $47.65 billion, a P/E ratio of 11.68, a PEG ratio of 3.95 and a beta of 1.08. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The firm's 50 day moving average price is $77.71 and its two-hundred day moving average price is $74.79. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, topping the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences's revenue was up 11.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.70 EPS. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. As a group, equities research analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 4,114 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company's stock, valued at $1,748,278.92. The trade was a 15.75% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Larry L. Wood sold 8,950 shares of the business's stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company's stock, valued at $16,150,614. This represents a 4.15% decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,584 shares of company stock valued at $1,897,762 in the last quarter. Company insiders own 0.34% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.